Cooper Companies (The) (COO) valuation
Cooper Companies (The) P/E ratio history
Cooper Companies (The) trades at 20.4 times its earnings over the last twelve months and 12.8 times the earnings analysts expect over the next twelve. At its last 10 fiscal year ends its P/E ranged from 7.1 (year to Oct 2021) to 92.9 (year to Oct 2018), with a median of 36.3.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Oct 31, 2025 | $69.91 | $1.87 | 37.4 | 16.1 |
| Oct 31, 2024 | $104.68 | $1.96 | 53.4 | 27.1 |
| Oct 31, 2023 | $77.94 | $1.48 | 52.7 | 22.5 |
| Oct 31, 2022 | $68.35 | $1.94 | 35.2 | 20.8 |
| Oct 31, 2021 | $104.23 | $14.79 | 7.1 | 29.1 |
| Oct 31, 2020 | $79.76 | $1.20 | 66.3 | — |
| Oct 31, 2019 | $72.75 | $2.33 | 31.2 | — |
| Oct 31, 2018 | $64.58 | $0.69 | 92.9 | — |
| Oct 31, 2017 | $60.06 | $1.88 | 32.0 | — |
| Oct 31, 2016 | $44.01 | $1.40 | 31.5 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Cooper Companies (The) valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Cooper Companies (The)COO | $11.6B | 20.4 | 12.8 | 2.7 |
| Bio-TechneTECH | $11.4B | 62.6 | 35.7 | 9.4 |
| Baxter InternationalBAX | $11.9B | — | 11.2 | 1.0 |
| Align TechnologyALGN | $10.7B | 26.1 | 12.5 | 2.6 |
| InsuletPODD | $10.4B | 28.1 | 21.0 | 3.4 |
| Charles River LaboratoriesCRL | $17.3B | — | 29.8 | 4.3 |
| RevvityRVTY | $17.5B | 75.1 | 27.9 | 6.0 |
| Zimmer BiometZBH | $18.3B | 22.9 | 10.8 | 2.2 |
| SterisSTE | $22.2B | 27.8 | 19.8 | 3.7 |
| Peer median | 27.9 | 20.4 | 3.5 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: COO financials · COO returns
No forecast, no recommendation. This page describes Cooper Companies (The) from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.